Pulmonary Hypertension Group III Workstream
Back to Task Forces & IDDI Workstreams
This Workstream was founded in March 2021 and serves as a collaborative platform between industry, academic, regulatory, and patient representatives. Its aim is to strengthen our community’s understanding of pulmonary hypertension due to lung diseases. Every month, the group holds scientific discussions, often featuring focus lectures and journal club sessions. If you’re interested in joining this Workstream, please get in touch.
The Workstream aims to improve the care and daily living of PH group III patients by:
- evaluating evidence and epidemiology
- defining different phenotypes and endophenotypes
- delineating innovative clinical trial design and endpoints
- identifying novel diagnostic, digital solutions, and treatment approaches
Continued work in 2025
PH Group III is focusing on COPD-PH publications including, Pathogenesis and Phenotypes and Management and Treatment combined with Clinical trial design and endpoints.
Publications
- Nathan, S.D., Piccari, L., Abman, S.H., Balasubramanian, A., Girgis, R.E., et al. (2025) 'Significance of pulmonary vascular dysfunction in chronic obstructive pulmonary disease'. Pulmonary Circulation, 15(3), e70144
- Vitulo, P., Piccari, L., Wort, S.J., Shlobin, O.A., Kovacs, G., et al. (2024) 'Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH‑CLD): A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative — Group 3 pulmonary hypertension'. Pulmonary Circulation, 14(4), e70005
- Shlobin, O.A., Shen, E., Wort, S.J., Piccari, L., Scandurra, J.A., et al. (2024) 'Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension'. Pulmonary Circulation, 14(1), e12310
- Piccari, L., Allwood, B., Antoniou, K., Chung, J.H., Hassoun, P.M., et al. (2023) 'Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative ‑ Group 3 Pulmonary Hypertension'. Pulmonary Circulation, 13(2), e12213
- Nathan, S.D., Fernandes, P., Psotka, M., Vitulo, P., Piccari, L., et al. (2022) 'Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute’s Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension'. Pulmonary Circulation, 12(4), e12178
- Nikkho, S.M., Richter, M.J., Shen, E., Abman, S.H., Antoniou, K., et al. (2022) 'Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 pulmonary hypertension'. Pulmonary Circulation, 12(3), e12127
Related articles by Workstream members
- Inhaled Treprostinil in PH associated with interstitial lung disease: hope on the horizon, Steven Nathan and Eric Shen, May 2022
- Tobacco Smoking as Risk for PH, Manuel Richter, February 2022
- PH in COPD an unmet clinical need, Dario Vizza, Lucilla Piccari and Oksana Shlobin, September 2021
- PH associated with chronic lung disease: a constellation of phenotypes, Lucilla Piccari, April 2021
- Will the INCREASE study leverage Group 3 PH awareness and interest? Steven Nathan, April 2021
PVRI 2024 Congress presentations
Leaders
Steven Nathan, Inova
Sylvia Nikkho, Bayer
Want to be part of something special?
All PVRI members are welcome to join an IDDI Workstream or a Task Force.
Our Regional Task Forces don't yet have global coverage. If you're interested in starting one, please contact us.
Interested in accessing global data on PH patient experience?
Almost 4,000 patients and carers across 85 countries completed Phase 1 of our PH Global Patient Survey (PHGPS). Questions across all PH groups included diagnostic tests & timelines, genetic testing, treatments, financial burdens, hospital visits, research participation, quality of life, telemedicine, patient-reported outcome measures, and self-monitoring with digital technology. The findings have the potential to improve patient care, guide future research and help us address unmet needs.